The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy
Authors:
- Yu XuYXYu Xu
- Qitian MuQMQitian Mu
- Lihong CaoLCLihong Cao
- Jian ChenJCJian Chen
- Zhijuan ZhuZZZhijuan Zhu
- Yinjun LouYLYinjun Lou
- Haitao MengHMHaitao Meng
- Wenbin QianWQWenbin Qian
- Hongyan TongHTHongyan Tong
- Wenyuan MaiWMWenyuan Mai
- Jian HuangJHJian Huang
- 19 August 2014
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (4) , 1027-1032
Abstract
The risk factors and the role of prophylactic antiviral therapy of hepatitis B virus (HBV) reactivation in patients with hepatitis B surface antigen (HBsAg) negative/hepatitis B core antibody (HBcAb) positive disease remain controversial. We reviewed 629 patients with diffuse large B-cell lymphoma (DLBCL). Among 629 patients, 150 of 246 patients with resolved HBV (HBsAg negative and HBcAb positive) were treated with rituximab-combined therapy. Among these 150 patients, none of 104 patients (0.0%) who were hepatitis B surface antibody (HBsAb) positive experienced HBV reactivation versus four of 46 patients (8.7%) who were HBsAb negative (p = 0.008). One of 113 patients (0.9%) with International Prognostic Index (IPI) 0-2 suffered HBV reactivation versus three of the remaining 37 patients (8.1%) with IPI 3-5 (p = 0.047). HBsAb and IPI are potential risk factors for HBV reactivation. The use of prophylactic agents may not be recommended for these patients until the occurrence of HBV reactivation.Keywords
This publication has 27 references indexed in Scilit:
- Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxisAnnals of Hematology, 2011
- Prospective Analysis of Hepatitis B Virus Reactivation in Patients With Diffuse Large B-Cell Lymphoma After Rituximab Combination ChemotherapyJournal of Clinical Oncology, 2010
- Reactivation of hepatitis B virus after rituximab‐containing treatment in patients with CD20‐positive B‐cell lymphomaCancer, 2010
- Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during ChemotherapyAnnals of Internal Medicine, 2008
- The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphomaAnnals of Hematology, 2008
- Chronic hepatitis BHepatology, 2007
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measuresJournal of Viral Hepatitis, 2004
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997